Inari Medical, Inc. (NARI)

NASDAQ: NARI · IEX Real-Time Price · USD
58.62
-0.08 (-0.14%)
At close: Feb 3, 2023, 4:00 PM
57.77
-0.85 (-1.45%)
After-hours: Feb 3, 2023, 4:23 PM EST
-0.14%
Market Cap 3.15B
Revenue (ttm) 358.92M
Net Income (ttm) -22.36M
Shares Out 53.65M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 665,491
Open 58.07
Previous Close 58.70
Day's Range 57.71 - 59.74
52-Week Range 50.50 - 100.00
Beta 1.21
Analysts Buy
Price Target 93.05 (+58.73%)
Earnings Date Feb 21, 2023

About NARI

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore s... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date May 22, 2020
Employees 800
Stock Exchange NASDAQ
Ticker Symbol NARI
Full Company Profile

Financial Performance

In 2021, Inari Medical's revenue was $276.98 million, an increase of 98.31% compared to the previous year's $139.67 million. Earnings were $9.84 million, a decrease of -28.64%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for NARI stock is "Buy." The 12-month stock price forecast is $93.05, which is an increase of 58.73% from the latest price.

Price Target
$93.05
(58.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...

4 days ago - GlobeNewsWire

Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues

Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.

3 weeks ago - Zacks Investment Research

Strength Seen in Inari Medical, Inc. (NARI): Can Its 5.6% Jump Turn into More Strength?

Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

3 weeks ago - Zacks Investment Research

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

1 month ago - Zacks Investment Research

Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference

IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suf...

1 month ago - GlobeNewsWire

Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y

Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.

3 months ago - Zacks Investment Research

Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 20.83% and 6.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Inari Medical Reports Third Quarter 2022 Financial Results

IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...

3 months ago - GlobeNewsWire

Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT

IRVINE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suff...

3 months ago - GlobeNewsWire

Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Inari Medical to Announce Third Quarter 2022 Financial Results

IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suf...

4 months ago - GlobeNewsWire

Inari Medical (NARI) Posts Positive Results of FLASH Registry

Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.

4 months ago - Zacks Investment Research

Inari Medical to Host First Analyst & Investor Day

IRVINE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from ven...

5 months ago - GlobeNewsWire

Inari Medical, Inc. (NARI) Down 16.4% Since Last Earnings Report: Can It Rebound?

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis

IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venou...

5 months ago - GlobeNewsWire

Inari Medical to Present at Upcoming Investor Conferences

IRVINE, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...

5 months ago - GlobeNewsWire

Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

6 months ago - Zacks Investment Research

Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Inari Medical Announces Leadership Succession Plan

Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023 Drew Hykes to Succeed Bill Hoffman as Chief Executive Officer in January 2023

6 months ago - GlobeNewsWire

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?

Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Inari Medical to Announce Second Quarter 2022 Financial Results

IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from veno...

7 months ago - GlobeNewsWire

OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDERS TO ADDRESS A WIDE RANGE OF PERIPHERAL EMBOLIZATION CASES

ALISO VIEJO, Calif. , June 7, 2022 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular ...

8 months ago - PRNewsWire

Inari Medical Announces Launch of 2021 Ethos and Sustainability Report

IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venou...

9 months ago - GlobeNewsWire

Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

9 months ago - Zacks Investment Research

Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus

Inari Medical Inc's (NASDAQ: NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million. The increase over the prior year was driven by continued U.S. ...

9 months ago - Benzinga